Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB).

1511Background: The clinical impact of addressing potentially GL alterations (PGA) from somatic next-generation sequencing (NGS) is not well characterized. We hypothesize that the addition of screening for PGA by genetics professionals at GTB increases GL findings in those who underwent NGS. Methods: In a prospectively accrued cohort with tumor NGS via FoundationOne (F1), we quantified (1) patients with ≥1 GC visit, (2) whether GC occurred pre- or post-F1 testing, (3) GC referrals due to F1 reports, (4) which had GL testing, and (5) results of GL testing. We analyzed these variables across 4 sub-cohorts: patients whose F1 reports were presented at GTB (C1) before and (C2) after the addition of screening for PGA by genetics professionals at GTB. C2 was further subdivided: (C2A) after the addition of GL screening at GTB and (C2B) after the addition of GL screening at GTB plus a formal CCG workflow to coordinate post-GTB GC. P-values were determined using a 2-sample, one-tailed z-test. Results: 907 F1 report...